Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016826
Chunk: 3

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 3
---
2023.

The selling shareholders
are identified in the table commencing on page 13. Each Depositary Share represents 100,000 Ordinary Shares. No Depositary Shares are
being registered hereunder for sale by us. We will not receive any proceeds from the sale of the Depositary Shares by the selling shareholders.
All net proceeds from the sale of the Ordinary Shares represented by Depositary Shares covered by this prospectus will go to the selling
shareholders. However, we may receive the proceeds from any exercise of warrants in certain circumstances. See “Use of Proceeds.”

The selling shareholders
may sell all or a portion of the Ordinary Shares represented by Depositary Shares from time to time in market transactions through any
market on which our Depositary Shares are then traded, in negotiated transactions or otherwise, and at prices and on terms that will be
determined by the then prevailing market price or at negotiated prices directly or through a broker or brokers, who may act as agent or
as principal or by a combination of such methods of sale. We will bear all of the expenses incurred in connection with the registration
of these shares. The selling shareholders will pay any underwriting discounts and selling commissions and/or similar charges incurred
in connection with the sale of the shares. See “Plan of Distribution.”

Our Depositary Shares
are listed on the NASDAQ Capital Market under the symbol “BDRX.” The last reported closing price of our Depositary Shares
on the NASDAQ Capital Market on November 14, 2025 was $5.26.

Investing in our securities involves risks. See “Risk Factors” beginning on page 9 of this prospectus and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

<div align='center'>___________________________________

The date of this prospectus is , 2025</div>

<div align='center'>TABLE OF CONTENTS</div>

|                                                         | Page |
| ABOUT THIS PROSPECTUS                                   |    1 |
| PRESENTATION OF FINANCIAL AND OTHER INFORMATION         |    2 |
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS    |    4 |
| PROSPECTUS SUMMARY                                      |    5 |
| RISK FACTORS                                            |